CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 116 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,106,536 | +43.5% | 37,207 | -13.1% | 0.00% | 0.0% |
| Q2 2023 | $771,183 | +51.4% | 42,796 | +34.9% | 0.00% | 0.0% |
| Q1 2023 | $509,424 | -6.2% | 31,720 | +6.9% | 0.00% | 0.0% |
| Q4 2022 | $543,181 | -11.1% | 29,682 | -4.5% | 0.00% | 0.0% |
| Q3 2022 | $611,000 | +19.6% | 31,066 | +13.2% | 0.00% | 0.0% |
| Q2 2022 | $511,000 | -6.6% | 27,436 | +10.1% | 0.00% | – |
| Q1 2022 | $547,000 | -5.2% | 24,930 | +22.7% | 0.00% | – |
| Q4 2021 | $577,000 | +89.8% | 20,317 | +41.3% | 0.00% | – |
| Q3 2021 | $304,000 | +13.0% | 14,382 | +0.6% | 0.00% | – |
| Q2 2021 | $269,000 | +68.1% | 14,290 | +36.2% | 0.00% | – |
| Q1 2021 | $160,000 | -38.7% | 10,492 | -43.2% | 0.00% | – |
| Q4 2020 | $261,000 | +23.7% | 18,470 | +53.2% | 0.00% | – |
| Q2 2020 | $211,000 | – | 12,057 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,030,616 | $31,028,000 | 6.04% |
| 5AM Venture Management, LLC | 1,362,286 | $20,816,000 | 3.75% |
| Burrage Capital Management LLC | 272,393 | $4,162,000 | 3.37% |
| Altium Capital Management LP | 361,930 | $5,530,000 | 1.54% |
| Vivo Capital, LLC | 2,214,138 | $33,832,000 | 1.19% |
| Bain Capital Life Sciences Investors, LLC | 1,071,428 | $16,371,000 | 0.93% |
| Perceptive Advisors | 3,659,381 | $51,606,000 | 0.65% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $2,154,000 | 0.50% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,003,688 | $30,616,000 | 0.45% |
| Opaleye Management Inc. | 188,000 | $2,873,000 | 0.42% |